Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
60 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Iron Deficiency Anemia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Iron Deficiency Anemia - Pipeline Review, H2 2014', provides an overview of the Iron Deficiency Anemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Iron Deficiency Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Iron Deficiency Anemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Iron Deficiency Anemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Iron Deficiency Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Iron Deficiency Anemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Iron Deficiency Anemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Iron Deficiency Anemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Iron Deficiency Anemia Overview 6 Therapeutics Development 7 Pipeline Products for Iron Deficiency Anemia - Overview 7 Pipeline Products for Iron Deficiency Anemia - Comparative Analysis 8 Iron Deficiency Anemia - Therapeutics under Development by Companies 9 Iron Deficiency Anemia - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Iron Deficiency Anemia - Products under Development by Companies 13 Iron Deficiency Anemia - Companies Involved in Therapeutics Development 14 AMAG Pharmaceuticals, Inc. 14 Rockwell Medical, Inc. 15 Po-ling Fujin Biotechnology Co., Ltd. 16 Vifor Pharma AG 17 Acino Pharma AG 18 Iron Deficiency Anemia - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 26 ferric pyrophosphate citrate - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ferumoxytol - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ST-10 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ferric citrate - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ferric carboxymaltose - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ferrous sulfate - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 VIT-91 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Iron Deficiency Anemia - Recent Pipeline Updates 38 Iron Deficiency Anemia - Dormant Projects 52 Iron Deficiency Anemia - Product Development Milestones 53 Featured News & Press Releases 53 Jul 15, 2014: American Regent's Injectafer (Ferric Carboxymaltose Injection) Now the Fastest Growing IV Iron in United States 53 Jun 09, 2014: Rockwell Medical Wins Appeal for Determination as Small Business for New Drug Application Filing for Triferic 53 Jun 06, 2014: AMAG Pharmaceuticals Announces Patent Term Extension for Ferumoxytol in the U.S. 54 May 28, 2014: Rockwell Medical Announces FDA Acceptance for Filing of Triferic New Drug Application 54 May 22, 2014: Keryx Receives Notification of PDUFA Date Extension for Zerenex 55 May 14, 2014: Rockwell Medical to Present Triferic Iron Replacement Clinical Data at 51st ERA-EDTA Congress in Amsterdam, The Netherlands, May 31 - June 3, 2014 56 May 01, 2014: American Regent's Injectafer (Ferric Carboxymaltose Injection) Assigned Q Code by Centers for Medicare and Medicaid Services 56 Apr 29, 2014: Rockwell Medical Announces Triferic Iron Replacement Clinical Data to be Presented at 14th Asian Pacific Congress of Nephrology May 14-17, 2014 in Tokyo, Japan 57 Apr 14, 2014: Rockwell Medical Announces Triferic Iron Replacement Clinical Data Selected for Three Abstract Presentations at National Kidney Foundation Spring Clinical Meetings April 22-26, 2014 in Las Vegas 57 Apr 09, 2014: Keryx Biopharmaceuticals Announces Zerenex Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting 58 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 60 Disclaimer 60
List of Tables Number of Products under Development for Iron Deficiency Anemia, H2 2014 7 Number of Products under Development for Iron Deficiency Anemia - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Iron Deficiency Anemia - Pipeline by AMAG Pharmaceuticals, Inc., H2 2014 14 Iron Deficiency Anemia - Pipeline by Rockwell Medical, Inc., H2 2014 15 Iron Deficiency Anemia - Pipeline by Po-ling Fujin Biotechnology Co., Ltd., H2 2014 16 Iron Deficiency Anemia - Pipeline by Vifor Pharma AG, H2 2014 17 Iron Deficiency Anemia - Pipeline by Acino Pharma AG, H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Number of Products by Stage and Target, H2 2014 20 Number of Products by Stage and Mechanism of Action, H2 2014 22 Number of Products by Stage and Route of Administration, H2 2014 24 Number of Products by Stage and Molecule Type, H2 2014 25 Iron Deficiency Anemia Therapeutics - Recent Pipeline Updates, H2 2014 38 Iron Deficiency Anemia - Dormant Projects, H2 2014 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
